MA47301B1 - Inhibiteurs sélectifs de jak1 - Google Patents

Inhibiteurs sélectifs de jak1

Info

Publication number
MA47301B1
MA47301B1 MA47301A MA47301A MA47301B1 MA 47301 B1 MA47301 B1 MA 47301B1 MA 47301 A MA47301 A MA 47301A MA 47301 A MA47301 A MA 47301A MA 47301 B1 MA47301 B1 MA 47301B1
Authority
MA
Morocco
Prior art keywords
selective jak1
jak1 inhibitors
formula
compounds
inhibitors
Prior art date
Application number
MA47301A
Other languages
English (en)
Other versions
MA47301A (fr
Inventor
Karl Nilsson
Annika Åstrand
Anna Berggren
Johan Johansson
Matti Lepistö
Sameer Kawatkar
Qibin Su
Jason Kettle
Original Assignee
Astrazeneca Ab 151 85 Soedertaelje
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab 151 85 Soedertaelje filed Critical Astrazeneca Ab 151 85 Soedertaelje
Publication of MA47301A publication Critical patent/MA47301A/fr
Publication of MA47301B1 publication Critical patent/MA47301B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne d'une manière générale des composés de formule (i) et des sels pharmaceutiquement acceptables de ceux-ci. Dans la formule (i), r1-r8 peuvent prendre une quelconque des significations définies dans la description. L'invention concerne également des compositions pharmaceutiques comprenant des composés de formule (i) et leurs procédés d'utilisation.
MA47301A 2017-01-17 2018-01-16 Inhibiteurs sélectifs de jak1 MA47301B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762447057P 2017-01-17 2017-01-17
PCT/EP2018/051038 WO2018134213A1 (fr) 2017-01-17 2018-01-16 Inhibiteurs sélectifs de jak1

Publications (2)

Publication Number Publication Date
MA47301A MA47301A (fr) 2019-11-27
MA47301B1 true MA47301B1 (fr) 2023-02-28

Family

ID=61024756

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47301A MA47301B1 (fr) 2017-01-17 2018-01-16 Inhibiteurs sélectifs de jak1

Country Status (38)

Country Link
US (4) US10961228B2 (fr)
EP (2) EP4219470A1 (fr)
JP (3) JP6986086B2 (fr)
KR (2) KR102585048B1 (fr)
CN (2) CN115925693B (fr)
AR (1) AR110753A1 (fr)
AU (1) AU2018209667B2 (fr)
CA (1) CA3049175A1 (fr)
CL (1) CL2019001993A1 (fr)
CO (1) CO2019007888A2 (fr)
CR (1) CR20190332A (fr)
DK (1) DK3571192T3 (fr)
DO (1) DOP2019000184A (fr)
EA (1) EA037067B1 (fr)
EC (1) ECSP19051352A (fr)
ES (1) ES2938648T3 (fr)
FI (1) FI3571192T3 (fr)
HR (1) HRP20230069T1 (fr)
HU (1) HUE061064T2 (fr)
IL (1) IL267851B (fr)
JO (1) JOP20190174B1 (fr)
LT (1) LT3571192T (fr)
MA (1) MA47301B1 (fr)
MX (2) MX390625B (fr)
MY (1) MY199735A (fr)
NI (1) NI201900077A (fr)
PE (1) PE20191108A1 (fr)
PH (1) PH12019501639B1 (fr)
PL (1) PL3571192T3 (fr)
PT (1) PT3571192T (fr)
RS (1) RS63981B1 (fr)
SG (1) SG11201906222WA (fr)
SI (1) SI3571192T1 (fr)
SM (1) SMT202300051T1 (fr)
TW (1) TWI753089B (fr)
UA (1) UA124246C2 (fr)
WO (1) WO2018134213A1 (fr)
ZA (1) ZA201906875B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018209667B2 (en) 2017-01-17 2020-05-07 Astrazeneca Ab JAK1 selective inhibitors
ES2890668T3 (es) 2017-01-26 2022-01-21 Hanmi Pharm Ind Co Ltd Compuesto de pirimidina y uso farmacéutico del mismo
WO2020016302A1 (fr) 2018-07-18 2020-01-23 Astrazeneca Ab Sel de xinafoate d'un composé inhibiteur de jak
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
US12234232B2 (en) 2018-09-21 2025-02-25 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Aromatic heterocyclic compound with kinase inhibitory activity
WO2020171646A1 (fr) 2019-02-22 2020-08-27 한미약품 주식회사 Composition pharmaceutique comprenant un inhibiteur flt3 et un agent hypométhylant pour le traitement de la leucémie myéloïde aiguë
AR118729A1 (es) * 2019-04-19 2021-10-27 Dizal Jiangsu Pharmaceutical Co Ltd Inhibidor selectivo de la jak1 quinasa
CA3145391A1 (fr) 2019-06-27 2020-12-30 Hanmi Pharm. Co., Ltd. Composition pharmaceutique pour le traitement de la leucemie myeloide aigue contenant un inhibiteur de flt3 et des agents de chimiotherapie
WO2021207302A1 (fr) * 2020-04-09 2021-10-14 Disarm Therapeutics, Inc. Dérivés d'indazole utiles en tant qu'inhibiteurs de sarm1
JP7613778B2 (ja) * 2020-11-26 2025-01-15 科輝智薬（深▲セン▼）新薬研究中心有限公司 アミド化合物、医薬組成物およびその使用
US20240190849A1 (en) * 2021-02-26 2024-06-13 Tyra Biosciences, Inc. Aminopyrimidine compounds and methods of their use
US12240836B2 (en) * 2022-07-05 2025-03-04 Dong-A St Co., Ltd. Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法
WO2024150110A1 (fr) * 2023-01-11 2024-07-18 Pfizer Inc. Compositions et méthodes pour le traitement et/ou la prévention du diabète de type 1
CN115974845B (zh) * 2023-01-19 2024-09-20 奥锐特药业股份有限公司 奥希替尼中间体的制备方法
US20240307353A1 (en) * 2023-03-16 2024-09-19 Incyte Corporation Jak1 pathway inhibitors for the treatment of asthma
GB202316063D0 (en) 2023-10-20 2023-12-06 Astrazeneca Ab Dosing regime
GB202403369D0 (en) 2024-03-08 2024-04-24 Astrazeneca Ab Process and intermediates for the production of a jak1 inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1799652A1 (fr) 2004-10-13 2007-06-27 Wyeth Analogues d'anilino-pyrimidine a substitution n-benzenesulfonyle
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
CN101421250A (zh) * 2006-01-30 2009-04-29 埃克塞里艾克西斯公司 作为jak-2调节剂的4-芳基-2-氨基-嘧啶或4-芳基-2-氨基烷基-嘧啶及包含它们的药物组合物
JP2010518025A (ja) * 2007-02-05 2010-05-27 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼ活性化タンパク質（ｆｌａｐ）インヒビターとしての逆インドール
WO2009046416A1 (fr) * 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines en tant qu'inhibiteurs de kinases jak
EP2207547A4 (fr) * 2007-10-05 2010-11-17 Amira Pharmaceuticals Inc Inhibiteurs de protéine activant la 5-lipoxygénase
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
EP3354652B1 (fr) 2010-03-10 2020-05-06 Incyte Holdings Corporation Dérivés de pipéridine-4-yl azétidine utilisés en tant qu'inhibiteurs de jak1
KR20130051507A (ko) * 2010-09-15 2013-05-20 에프. 호프만-라 로슈 아게 아자벤조티아졸 화합물, 조성물 및 사용 방법
WO2015061665A1 (fr) 2013-10-24 2015-04-30 Abbvie Inc. Inhibiteur sélectif de jak1 et ses utilisations
JP6767491B2 (ja) 2015-09-25 2020-10-14 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｊａｋを阻害するための化合物及び方法
AU2018209667B2 (en) * 2017-01-17 2020-05-07 Astrazeneca Ab JAK1 selective inhibitors

Also Published As

Publication number Publication date
KR102659213B1 (ko) 2024-04-18
CN115925693B (zh) 2024-11-12
MA47301A (fr) 2019-11-27
US11897869B2 (en) 2024-02-13
JP2024010041A (ja) 2024-01-23
IL267851B (en) 2021-08-31
SI3571192T1 (sl) 2023-03-31
KR20190104215A (ko) 2019-09-06
MX390625B (es) 2025-03-19
UA124246C2 (uk) 2021-08-11
AU2018209667B2 (en) 2020-05-07
JP2020506171A (ja) 2020-02-27
CA3049175A1 (fr) 2018-07-26
US10961228B2 (en) 2021-03-30
JOP20190174B1 (ar) 2023-09-17
EA201991700A1 (ru) 2020-01-28
JP7394820B2 (ja) 2023-12-08
PH12019501639B1 (en) 2023-09-08
US12473272B2 (en) 2025-11-18
TWI753089B (zh) 2022-01-21
HRP20230069T1 (hr) 2023-03-17
US20190367490A1 (en) 2019-12-05
DK3571192T3 (da) 2023-02-06
NZ756069A (en) 2025-08-29
KR20230141938A (ko) 2023-10-10
JP2022043059A (ja) 2022-03-15
RS63981B1 (sr) 2023-03-31
EP4219470A1 (fr) 2023-08-02
CL2019001993A1 (es) 2019-12-27
PL3571192T3 (pl) 2023-03-20
AR110753A1 (es) 2019-05-02
JP6986086B2 (ja) 2021-12-22
MX418519B (es) 2024-12-09
CN110461830B (zh) 2022-11-01
EP3571192B1 (fr) 2022-11-30
MX2022002976A (es) 2022-04-06
ECSP19051352A (es) 2019-07-31
CO2019007888A2 (es) 2019-07-31
DOP2019000184A (es) 2019-08-15
CR20190332A (es) 2019-09-13
LT3571192T (lt) 2023-02-27
SG11201906222WA (en) 2019-08-27
WO2018134213A1 (fr) 2018-07-26
US20260028329A1 (en) 2026-01-29
PE20191108A1 (es) 2019-08-26
SMT202300051T1 (it) 2023-03-17
CN115925693A (zh) 2023-04-07
ES2938648T3 (es) 2023-04-13
AU2018209667A1 (en) 2019-08-22
IL267851A (en) 2019-09-26
BR112019014526A2 (pt) 2020-02-27
ZA201906875B (en) 2021-05-26
PH12019501639A1 (en) 2020-07-06
KR102585048B1 (ko) 2023-10-05
PT3571192T (pt) 2023-02-21
NI201900077A (es) 2020-03-18
JP7626819B2 (ja) 2025-02-04
FI3571192T3 (fi) 2023-03-06
JOP20190174A1 (ar) 2019-07-14
TW201838984A (zh) 2018-11-01
US20210188821A1 (en) 2021-06-24
HUE061064T2 (hu) 2023-05-28
MY199735A (en) 2023-11-21
US20240208947A1 (en) 2024-06-27
EP3571192A1 (fr) 2019-11-27
EA037067B1 (ru) 2021-02-02
CN110461830A (zh) 2019-11-15
MX2019008435A (es) 2019-09-09

Similar Documents

Publication Publication Date Title
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MA45920B1 (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA38175B1 (fr) Lactames fusionnés à un aryle et hétéroaryle
MA47079B1 (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MX390625B (es) Inhibidores selectivos de jak1.
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
DOP2012000314A (es) Compuestos, composiciones de tiocetato y metodos de uso
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
EA200971081A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA39995B1 (fr) Composés destinés à traiter l'amyotrophie spinale
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
BR112015022551A2 (pt) inibidores de amido pirrol
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
ECSP10010310A (es) Nuevos compuestos y composiciones y métodos de uso
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA37831A1 (fr) Dérivés d'azaindole agissant comme inhibiteur de pi3k